ENZALUTAMIDE HISTORY

Enzalutamide medication is the only medication of second-generation NSAA which is approved to date. Enzalutamide is a nonsteroidal antiandrogen used for the treatment of patients with castration-resistant prostate cancer, and metastatic castration- sensitive prostate cancer. 

In 1995, Bicalutamide (Casodex) introduced and approved by the NSAA for the treatment of prostate cancer because of its effectiveness, safety, and suitability. Bicalutamide has had a worldwide medication for prostate cancer.

Enzalutamide (years back called MDV3100) was first detailed by Charles Sawyers and Michael Jung in 2006 at the University of California, Los Angeles. Enzalutamide evaluated from 200 combinations of nonsteroidal antiandrogen prostate cells as a model.

At the same time of approval, the medication was conducting other randomized tests, placebo-controlled, phase III trial in asymptomatic or delicate symptomatic patients with chemotherapy-naive (mCRPC). The main objective was to evaluate the efficiency and safety of Enzalutamide medication in patients who had not received cytotoxic chemotherapy. The Enzalutamide trial was examined and cleared to have positive results and was first showed in February 2014.

RD162 and Enzalutamide, two lead compounds were suggested, as identified Enzalutamide and selected based on the favorable drug.

DEVELOPMENT HISTORY:

The first approval for second-generation medication Enzalutamide (Xtandi) for the treatment of the particular patient with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) by the US Food and Drug Administration was on 31 August 2012. Xtandi's generic drug named as  Enzalutamide.  Sometimes, doctors and professionals may use a generic application name Enzalutamide when asking a patient to consume a trade drug called Xtandi.

DOSE:

The advised dose is Enzalutamide 40mg (4 capsules) should be taken orally by mouth. The drug is used in the treatment of Prostate Cancer. Sometimes, depends on the patient's history and body it prevents androgens from working within the prostate cancer cells. 

At the time of approval by the FDA of Xtandi (Enzalutamide 40 mg) capsule by Astellas Pharma Inc. was only brand intake was there. After that there is another brand name marketed under the same generic of Enzalutamide which are:

  • Bdenz by BDR Pharmaceuticals 
  • Azel by Dr. Reddy’s Laboratories
  • Glenza by Glenmark Pharmaceuticals
  •  Enzamide  by Intas Pharmaceuticals
  • Enzuta by Emcure Pharmaceutical

COST:

If we talk about the Enzalutamide cost of brand name Xtandi it is approximately Rs. 50,000/per bottle which consists of around 120 capsules.

Other than that Xtandi brands name i.e., Bdenz costs approximately Rs. 21500.

Comments

  1. I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
    liver already present. I started on antiviral medications which
    reduced the viral load initially. After a couple of years the virus
    became resistant. I started on HEPATITIS B Herbal treatment from
    ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
    treatment totally reversed the virus. I did another blood test after
    the 6 months long treatment and tested negative to the virus. Amazing
    treatment! This treatment is a breakthrough for all HBV carriers.

    ReplyDelete

Post a Comment

Popular posts from this blog

Trodelvy: All about the drug

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Buy Trodelvy sacituzumab govitecan-hziy in India